Indexado en

Licencia y uso

Citaciones

Altmetrics

Análisis de autorías institucional

Pina, Jose Javier BerenguerAutor o Coautor

Compartir

Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter study

Publicado en:Acta Oncologica. 63 213-219 - 2024-04-21 63(), DOI: 10.2340/1651-226X.2024.24179

Autores: Miceli, Rosalba; Eriksson, Hanna; Lo Russo, Giuseppe; Alfieri, Salvatore; Bjaanaes, Maria Moksnes; Pietrantonio, Filippo; De Cecco, Loris; Proto, Claudia; Franzen, Johan; McDonnell, Deirdre; Pina, Jose Javier Berenguer; Beninato, Teresa; Mazzeo, Laura; Giannatempo, Patrizia; Verzoni, Elena; Crown, John; Helland, Aslaug; Eustace, Alexander J

Afiliaciones

Resumen

Background: Immune checkpoint inhibitors (ICIs) have significantly improved outcomes in various cancers. ICI treatment is associated with the incidence of immune-related adverse events (irAEs) which can affect any organ. Data on irAEs occurrence in relation to sex- differentiation and their association with gender-specific factors are limited. Aims: The primary objective of the G-DEFINER study is to compare the irAEs incidence in female and male patients who undergo ICI treatment. Secondary objectives are: to compare the irAEs incidence in pre- and postmenopausal female patients; to compare the irAEs incidence in female and male patients according to different clinical and gender-related factors (lifestyle, psychosocial, and behavioral factors). Exploratory objectives of the study are to compare and contrast hormonal, gene-expression, SNPs, cytokines, and gut microbiota profiles in relation to irAEs incidence in female and male patients. Methods and Results: The patients are recruited from Fondazione IRCCS Istituto Nazionale dei Tumori, Italy, St Vincent's University Hospital, Ireland, Oslo University Hospital, Norway, and Karolinska Insitutet/ Karolinska University Hospital, Sweden. The inclusion of patients was delayed due to the Covid pandemic, leading to a total of 250 patients recruited versus a planned number of 400 patients. Clinical and translational data will be analyzed. Interpretation: The expected outcomes are to improve the management of cancer patients treated with ICIs, leading to more personalized clinical approaches that consider potential toxicity profiles. The real world nature of the trial makes it highly applicable for timely irAEs diagnosis.

Palabras clave